Permanently removing wheat, barley and rye is the only treatment that works for confirmed celiac disease, its blistering skin form, and gluten-linked balance problems. For everyone else the case is weaker, and the costs — lost whole grain and fibre, poorer substitutes, higher price — are better established. Testing must come first: the tests stop working once gluten is gone. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Tissue transglutaminase IgA | Negative (below assay cut-off) by 12 months | Confirms celiac diagnosis and, later, completeness of exclusion |
| Total immunoglobulin A | Above 70 mg/dL (age-adjusted) | Detects selective deficiency that makes the primary celiac test falsely negative |
| Ferritin | 50–150 ng/mL (women), 75–200 ng/mL (men) | Iron stores fall with malabsorption and with loss of fortified wheat products |
| 25-hydroxyvitamin D | 40–60 ng/mL | Absorption is impaired in active disease and intake falls on the diet at every age |
| Vitamin B12 | 500–900 pg/mL | Loss of fortified cereals plus ileal involvement depletes stores |
| Red blood cell folate | 400–800 ng/mL | Gluten-free flours are rarely fortified with folate, unlike wheat flour in many countries |
| Red blood cell magnesium | 4.2–6.8 mg/dL | Intake is insufficient on the diet, particularly in adolescence |
| High-sensitivity C-reactive protein | Below 1.0 mg/L | Tracks systemic inflammation, which falls as the mucosa heals |
| Lipid panel with apolipoprotein B | Apolipoprotein B below 80 mg/dL | Captures both the favourable HDL shift and any adverse move from refined gluten-free substitutes |
| HbA1c | 4.8–5.4% | Detects glycaemic drift from refined gluten-free starches replacing whole grain |
| Bone mineral density (DEXA) | T-score above −1.0 | Bone loss is the clinically important consequence of long-standing malabsorption |
| Urinary or stool gluten immunogenic peptides | Not detected | Objectively verifies exclusion when antibody results and symptoms disagree |
Cadence: Baseline before any gluten is removed; 3 months for symptoms and adherence; 6 and 12 months for antibody blood tests and the nutritional panel; every 12 months once stable; bone-density scan every 2–3 years where baseline was abnormal.